Trial Profile

Disposition of [14C]LY2603618 Following Intravenous Administration in Patients With Advanced and/or Metastatic Solid Tumors.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Jan 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Pemetrexed (Primary) ; Rabusertib (Primary)
Indications Solid tumours
Focus Pharmacokinetics
Sponsors Eli Lilly and Company

Most Recent Events

26 Apr 2012 Actual end date (February 2012) added as reported by ClinicalTrials.gov.
26 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
15 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com